Article Figures & Data
Figures
- Fig 1.
A, T2 and contrast enhancing contours overlaid on a GRE EPI and corresponding resampled T2* signal intensity time curves. B, Plot of T2* signal intensity time curve, S(t), for one voxel with red solid arrow denoting the time of contrast agent injection. C, Relative concentration curve obtained. Peak height is the distance from 1 to 2, while percent recovery represents how much the post-bolus signal (3) has recovered from the peak (2).
- Fig 2.
A, Histogram of intensities for the first time point, used to exclude tumor, ventricles, and large vessels from normal appearing brain tissue. B, Normal voxels selected using histogram analysis. C, The model function that results from averaging ΔR2* curves for all voxels displayed in B, used to normalize peak height values between patients.
- Fig 3.
Example of abnormal peak height (aPH; left) and abnormal recovery (aRec; center) maps for grade IV (top) and grade III (bottom) gliomas overlaid on a T2-weighted image (top -FSE, bottom –FLAIR) and the ΔR2* curves from which they were derived (right). The grade IV glioma demonstrates a large area of aPH (green) and aRec (magenta) near the center of the lesion while in the grade III glioma both aPH and aRec are more peripherally located.
Tables
- TABLE 1:
Volumes of abnormality expressed as percentages of the lesion on T2-weighted imaging
Finding Grade III Grade IV P Value Contrast enhancing 9.8 ± 12.3 32.7 ± 18.5 <.01 No decrease in signal intensity 7.6 ± 10.7 21.6 ± 22.7 <.02 Abnormal peak height 13.0 ± 10.0 24.9 ± 15.8 <.01 Abnormal recovery 10.1 ± 16.7 22.7 ± 16.9 <.001 - TABLE 2:
Relative peak height and recovery values in and surrounding contrast-enhancing lesions
Finding Grade III Grade IV P Value Relative peak height Contrast enhancing Mean 1.2 ± 0.8 2.0 ± 0.9 <.5 Maximum 2.3 ± 1.6 6.0 ± 3.2 <.002 T2 − enhancing Mean 1.1 ± 0.4 1.2 ± 0.5 >.99 Maximum 5.7 ± 2.7 5.8 ± 2.6 >.5 Percent Recovery Contrast enhancing Mean 80.4 ± 11.4 77.5 ± 6.7 <.01 Minimum 71.1 ± 13.4 47.7 ± 17.6 >.1 T2 − enhancing* Mean 83.7 ± 6.2 82.2 ± 4.7 >.1 Minimum 56.1 ± 14.6 43.3 ± 18.5 >.5 Finding Grade III Grade IV P Value Relative peak height Contrast enhancing 1.1 ± 0.9 2.1 ± 1.6 <.001 T2 − enhancing 1.0 ± 0.9 1.2 ± 1.0 >.1 Percent Recovery Contrast enhancing 82.5 ± 10.5 76.4 ± 11.8 <.001 T2 − enhancing* 84.9 ± 8.8 80.9 ± 10.6 <.01 - TABLE 4:
Relative peak height and recovery values for nonenhancing lesions on T2-weighted images
Finding Nonenhancing, Grade III T2 − Enhancing,* Grade IV Relative peak height Mean 1.2 ± 0.4 1.2 ± 0.5 Maximum 5.7 ± 2.8 5.8 ± 2.6 Recovery (%) Mean 86.4 ± 3.4 82.2 ± 4.9 Minimum 58.8 ± 12 43.3 ± 18.5 * T2 lesion excluding contrast enhancement.
In this issue
Jump to section
Related Articles
Cited By...
- Multi-Parametric and Multi-Regional Histogram Analysis of MRI: Revealing Imaging Phenotypes of Glioblastoma Correlated with Patient Survival
- ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain
- Multimodality Assessment of Brain Tumors and Tumor Recurrence
- Percentage Signal Recovery Derived from MR Dynamic Susceptibility Contrast Imaging Is Useful to Differentiate Common Enhancing Malignant Lesions of the Brain
- Contrast-Enhanced MR Imaging in Acute Ischemic Stroke: T2* Measures of Blood-Brain Barrier Permeability and Their Relationship to T1 Estimates and Hemorrhagic Transformation
- An Automatic Procedure for Normalization of Cerebral Blood Volume Maps in Dynamic Susceptibility Contrast-Based Glioma Imaging
- Distinguishing Recurrent Intra-Axial Metastatic Tumor from Radiation Necrosis Following Gamma Knife Radiosurgery Using Dynamic Susceptibility-Weighted Contrast-Enhanced Perfusion MR Imaging
- Magnetic Resonance Imaging Determination of Tumor Grade and Early Response to Temozolomide in a Genetically Engineered Mouse Model of Glioma
- Usefulness of diffusion/perfusion-weighted MRI in patients with non-enhancing supratentorial brain gliomas: a valuable tool to predict tumour grading?
- Diffusely Infiltrative Low-Grade Gliomas in Adults